TY - JOUR
T1 - IFN-γ activation of mesenchymal stem cells for treatment and prevention of graft versus host disease
AU - Polchert, David
AU - Sobinsky, Justin
AU - Douglas, G. W.
AU - Kidd, Martha
AU - Moadsiri, Ada
AU - Reina, Eduardo
AU - Genrich, Kristyn
AU - Mehrotra, Swati
AU - Setty, Suman
AU - Smith, Brett
AU - Bartholomew, Amelia
PY - 2008/6
Y1 - 2008/6
N2 - Graft versus host disease (GVHD), mediated by donor T cells, is a significant source of morbidity and mortality following allogeneic stem cell transplantation. Mesenchymal stem cells (MSC) can successfully treat ongoing graft versus host disease, presumably due to their ability to suppress donor T cell proliferation. Little is known about the potential of MSC to prevent GVHD. Here we show that bone marrow-isolated MSC can suppress the development of GVHD if given after donor T cell recognition of antigen. IFN-γ was required to initiate MSC efficacy. Recipients of IFN-γ-/- T cells did not respond to MSC treatment and succumbed to GVHD. MSC, pre-treated with IFN-c, became immediately active and could suppress GVHD more efficiently than a fivefold-greater number of MSC that were not activated. When given at the time of bone marrow transplantation, activated MSC could prevent GVHD mortality (100% survival, p=0.006). MSC activation was dependent on the magnitude of IFN-γ exposure, with increased IFN-γ exposure leading to increased MSC suppression of GVHD. Activated MSC present a new strategy for preventing GVHD using fewer MSC.
AB - Graft versus host disease (GVHD), mediated by donor T cells, is a significant source of morbidity and mortality following allogeneic stem cell transplantation. Mesenchymal stem cells (MSC) can successfully treat ongoing graft versus host disease, presumably due to their ability to suppress donor T cell proliferation. Little is known about the potential of MSC to prevent GVHD. Here we show that bone marrow-isolated MSC can suppress the development of GVHD if given after donor T cell recognition of antigen. IFN-γ was required to initiate MSC efficacy. Recipients of IFN-γ-/- T cells did not respond to MSC treatment and succumbed to GVHD. MSC, pre-treated with IFN-c, became immediately active and could suppress GVHD more efficiently than a fivefold-greater number of MSC that were not activated. When given at the time of bone marrow transplantation, activated MSC could prevent GVHD mortality (100% survival, p=0.006). MSC activation was dependent on the magnitude of IFN-γ exposure, with increased IFN-γ exposure leading to increased MSC suppression of GVHD. Activated MSC present a new strategy for preventing GVHD using fewer MSC.
KW - GVH disease
KW - IFN-γ
KW - Mesenchymal stem cell
UR - http://www.scopus.com/inward/record.url?scp=49649106257&partnerID=8YFLogxK
U2 - 10.1002/eji.200738129
DO - 10.1002/eji.200738129
M3 - Article
C2 - 18493986
AN - SCOPUS:49649106257
SN - 0014-2980
VL - 38
SP - 1745
EP - 1755
JO - European Journal of Immunology
JF - European Journal of Immunology
IS - 6
ER -